PubMed

Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density.

Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, Dasilva C, Santora AC, Ince BA.

J Bone Miner Res. 2009 Oct 29. [Epub ahead of print]PMID: 19874198 [PubMed - as supplied by publisher]Related articles

Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.

Davison KS, Kendler DL, Ammann P, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, McClung MR, Olszynski WP, Yuen CK.

Am J Med. 2009 Nov;122(11):992-7. Review.PMID: 19854322 [PubMed - indexed for MEDLINE]Related articles

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial.

N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914. PMID: 19671655 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.

Bone. 2009 Mar;44(3):418-22. Epub 2008 Oct 7.PMID: 18950736 [PubMed - indexed for MEDLINE]Related articles

European guidance for osteoporosis: an American perspective.

McClung MR.

Pol Arch Med Wewn. 2008 Sep;118(9):462-3. No abstract available. PMID: 18846979 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study Group.

Bone. 2008 Aug;43(2):222-9. Epub 2008 Apr 26.PMID: 18539106 [PubMed - indexed for MEDLINE]Related articles

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.

Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP, Recker RR, McClung MR.

Osteoporos Int. 2008 Jul;19(7):1039-45. Epub 2007 Dec 18.PMID: 18087660 [PubMed - indexed for MEDLINE]Related articles

Effects of risedronate on fracture risk in postmenopausal women with osteopenia.

Siris ES, Simon JA, Barton IP, McClung MR, Grauer A.

Osteoporos Int. 2008 May;19(5):681-6. Epub 2007 Oct 30.PMID: 17968610 [PubMed - indexed for MEDLINE]Related articlesFree article

Fracture risk remains reduced one year after discontinuation of risedronate.

Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A.

Osteoporos Int. 2008 Mar;19(3):365-72. Epub 2007 Oct 16.PMID: 17938986 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.

Bone. 2008 Jan;42(1):36-42. Epub 2007 Sep 8.PMID: 17920005 [PubMed - indexed for MEDLINE]Related articles

Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.

Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR.

J Clin Endocrinol Metab. 2007 Dec;92(12):4671-7. Epub 2007 Aug 28.PMID: 17726081 [PubMed - indexed for MEDLINE]Related articlesFree article

Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.

Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA; AMG 162 Bone Loss Study Group.

J Bone Miner Res. 2007 Dec;22(12):1832-41.PMID: 17708711 [PubMed - indexed for MEDLINE]Related articles

Looking for answers in all the wrong places.

McClung MR.

Menopause. 2007 Jan-Feb;14(1):7-9. No abstract available. PMID: 17194959 [PubMed - indexed for MEDLINE]Related articles

Bisphosphonates and osteonecrosis of the jaw.

Watts NB, Harris ST, McClung MR, Bilezikian JP, Greenspan SL, Luckey MM.

Ann Intern Med. 2006 Nov 21;145(10):791-2; author reply 792. No abstract available. PMID: 17116933 [PubMed - indexed for MEDLINE]Related articlesFree article

Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.

Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR.

Contraception. 2006 Aug;74(2):90-9. Epub 2006 May 19.PMID: 16860045 [PubMed - indexed for MEDLINE]Related articles

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.

Menopause. 2006 May-Jun;13(3):377-86.PMID: 16735934 [PubMed - indexed for MEDLINE]Related articles

Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.

McClung MR.

Curr Osteoporos Rep. 2006 Mar;4(1):28-33. Review.PMID: 16527005 [PubMed - indexed for MEDLINE]Related articles

Denosumab in postmenopausal women with low bone mineral density.

McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group.

N Engl J Med. 2006 Feb 23;354(8):821-31.PMID: 16495394 [PubMed - indexed for MEDLINE]Related articlesFree article

Do current management strategies and guidelines adequately address fracture risk?

McClung MR.

Bone. 2006 Feb;38(2 Suppl 2):S13-7. Epub 2006 Jan 3. Review.PMID: 16403495 [PubMed - indexed for MEDLINE]Related articles

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.

McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF.

Arch Intern Med. 2005 Aug 8-22;165(15):1762-8. Erratum in: Arch Intern Med. 2005 Oct 10;165(18):2120. PMID: 16087825 [PubMed - indexed for MEDLINE]Related articlesFree article

The relationship between bone mineral density and fracture risk.

McClung MR.

Curr Osteoporos Rep. 2005 Jun;3(2):57-63. Review.PMID: 16036103 [PubMed - indexed for MEDLINE]Related articles

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.

Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C.

J Bone Miner Res. 2005 Aug;20(8):1315-22. Epub 2005 Mar 14.PMID: 16007327 [PubMed - indexed for MEDLINE]Related articles

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD.

Osteoporos Int. 2006 Feb;17(2):159-66. Epub 2005 Jun 14. Review.PMID: 15959614 [PubMed - indexed for MEDLINE]Related articles

Osteopenia: to treat or not to treat?

McClung MR.

Ann Intern Med. 2005 May 3;142(9):796-7. No abstract available. PMID: 15867413 [PubMed - indexed for MEDLINE]Related articlesFree article

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK.

Endocr Rev. 2005 Aug;26(5):688-703. Epub 2005 Mar 15. Review.PMID: 15769903 [PubMed - indexed for MEDLINE]Related articlesFree article

Changes in bone density and turnover after alendronate or estrogen withdrawal.

Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC 2nd; Early Postmenopausal Intervention Cohort Study Group.

Menopause. 2004 Nov-Dec;11(6 Pt 1):622-30.PMID: 15545790 [PubMed - indexed for MEDLINE]Related articles

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P.

J Am Geriatr Soc. 2004 Nov;52(11):1832-9.PMID: 15507059 [PubMed - indexed for MEDLINE]Related articles

Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.

McClung MR, Wasnich RD, Hosking DJ, Christiansen C, Ravn P, Wu M, Mantz AM, Yates J, Ross PD, Santora AC 2nd; Early Postmenopausal Intervention Cohort Study.

J Clin Endocrinol Metab. 2004 Oct;89(10):4879-85.PMID: 15472179 [PubMed - indexed for MEDLINE]Related articlesFree article

Official positions of the international society for clinical densitometry.

Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr; International Society for Clinical Densitometry.

J Clin Endocrinol Metab. 2004 Aug;89(8):3651-5.PMID: 15292281 [PubMed - indexed for MEDLINE]Related articlesFree article

Pathogenesis of osteoporotic hip fractures.

McClung MR.

Clin Cornerstone. 2003;Suppl 2:S22-9. Review.PMID: 15035556 [PubMed - indexed for MEDLINE]Related articles

Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment.

Olszynski WP, Shawn Davison K, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris SP, Hodsman AB, Kendler D, McClung MR, Miller PD, Yuen CK.

Clin Ther. 2004 Jan;26(1):15-28. Review.PMID: 14996514 [PubMed - indexed for MEDLINE]Related articles

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group.

J Bone Miner Res. 2004 Jan;19(1):11-8.PMID: 14753731 [PubMed - indexed for MEDLINE]Related articles

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR; AACE Osteoporosis Task Force.

Endocr Pract. 2003 Nov-Dec;9(6):544-64. No abstract available. Erratum in: Endocr Pract. 2004 Jan-Feb;10(1):90. Endocr Pract. multiple author names added. PMID: 14715483 [PubMed - indexed for MEDLINE]Related articlesFree article

Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures.

Siris ES, Bilezikian JP, Rubin MR, Black DM, Bockman RS, Bone HG, Hochberg MC, McClung MR, Schnitzer TJ.

J Clin Endocrinol Metab. 2003 Aug;88(8):3482-6. Review.PMID: 12915621 [PubMed - indexed for MEDLINE]Related articlesFree article

The menopause and HRT. Prevention and management of osteoporosis.

McClung MR.

Best Pract Res Clin Endocrinol Metab. 2003 Mar;17(1):53-71. Review.PMID: 12763512 [PubMed - indexed for MEDLINE]Related articles

Bisphosphonates.

McClung MR.

Endocrinol Metab Clin North Am. 2003 Mar;32(1):253-71. Review.PMID: 12699302 [PubMed - indexed for MEDLINE]Related articles

The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.

Tankó LB, McClung MR, Schimmer RC, Mahoney P, Christiansen C.

Bone. 2003 Apr;32(4):421-6.PMID: 12689686 [PubMed - indexed for MEDLINE]Related articles

How does raloxifene reduce fracture risk?

McClung MR.

Menopause. 2002 Sep-Oct;9(5):306-8. Review. No abstract available. PMID: 12218718 [PubMed - indexed for MEDLINE]Related articles

Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.

Steinbuch M, D'Agostino RB, Mandel JS, Gabrielson E, McClung MR, Stemhagen A, Hofman A.

Regul Toxicol Pharmacol. 2002 Jun;35(3):320-6.PMID: 12202047 [PubMed - indexed for MEDLINE]Related articles

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.

Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R.

Calcif Tissue Int. 2002 Aug;71(2):103-11. Epub 2002 Jun 27.PMID: 12085156 [PubMed - indexed for MEDLINE]Related articles

Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, Smith ME, DeLucca P, Gormley GJ, Melton ME.

Ann Intern Med. 2002 May 21;136(10):742-6.PMID: 12020142 [PubMed - indexed for MEDLINE]Related articlesFree article

A national random survey of bone mineral density reporting in the United States.

El-Hajj Fuleihan G, Stock JL, McClung MR, Saifi G.

J Clin Densitom. 2002 Spring;5(1):3-9.PMID: 11940723 [PubMed - indexed for MEDLINE]Related articles

Bisphosphonates in osteoporosis: recent clinical experience.

McClung MR.

Expert Opin Pharmacother. 2000 Jan;1(2):225-38. Review.PMID: 11249544 [PubMed - indexed for MEDLINE]Related articles

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group.

N Engl J Med. 2001 Feb 1;344(5):333-40.PMID: 11172164 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice.

McClung MR.

Ann Med Interne (Paris). 2000 Sep;151(5):392-8. Review.PMID: 11033474 [PubMed - indexed for MEDLINE]Related articles

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.

Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE.

J Clin Endocrinol Metab. 2000 Apr;85(4):1492-7.PMID: 10770187 [PubMed - indexed for MEDLINE]Related articlesFree article

Blood pressure and calcium intake are related to bone density in adult males.

Metz JA, Morris CD, Roberts LA, McClung MR, McCarron DA.

Br J Nutr. 1999 May;81(5):383-8.PMID: 10615210 [PubMed - indexed for MEDLINE]Related articles

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G.

Ann Intern Med. 1999 Dec 21;131(12):935-42.PMID: 10610644 [PubMed - indexed for MEDLINE]Related articlesFree article

Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group.

Cook DJ, Guyatt GH, Adachi JD, Epstein RS, Juniper EF, Austin PA, Clifton J, Rosen CJ, Kessenich CR, Stock JL, Overdorf J, Miller PD, Erickson AL, McCLung MR, McClung BL, Griffith LE, Ioannidis G.

Osteoporos Int. 1999;10(3):207-13.PMID: 10525712 [PubMed - indexed for MEDLINE]Related articles

Therapy for fracture prevention.

McClung MR.

JAMA. 1999 Aug 18;282(7):687-9. No abstract available. PMID: 10517723 [PubMed - indexed for MEDLINE]Related articles